Save 80% of Time and Money on FDA 2253 Submissions
Zinc Ahead has announced a game-changing ability to directly submit post-marketing submissions through the FDA’s electronic submissions gateway, saving clients 80% of the time and money involved in this previously time-consuming process.
The FDA recently announced that from 15 June 2015 they will accept Promotional 2253 submissions in eCTD using the new Module 1 (v3.3). Life Sciences companies will be required to submit all Post-marketing Promotional Materials (Form FDA 2253 Submissions) and Pre-submissions of Promotional Materials for Accelerated Approval Products (subpart H and subpart E) electronically 24 months after their final guidance is issued.
Zinc’s flagship product, Zinc MAPS, offers an end-to-end process which facilitates the review, approval and direct eCTD submission to the FDA gateway in a contained, compliant software solution and will be available on the date that the gateway opens. No other third party integration products are required.
Zinc clients have the option to either directly submit the eCTD Submission package from Zinc MAPS to the FDA ESG or they can choose to have the eCTD Submission package delivered to their desktop or a secure server.
“Zinc continues to monitor the industry and stay ahead of its clients’ needs through continuous innovation in its product solutions,” said Dom Eaton, President of Product & Professional Services at Zinc. “Our latest enhancement to the Zinc MAPS product provides our clients a solution to streamline a submission resulting in reduced time and costs associated with compiling, packaging and shipping submissions to the FDA. Our clients can realize a savings of up to 80% with this solution versus manual submission preparation and physical materials.”
Zinc will enhance this functionality with the release of Zinc MAPS v15 which will convert the 2253 submission package into a validated eCTD format. Other enhancements to the 2253 submission process in Zinc MAPS v15 include the ability to create multiple submissions for jobs containing products from different centers and/or application types, the ability to edit submissions before sending to the FDA, the ability to create submissions of jobs that share a primary or secondary brand, the ability for the 2253 Admin to filter jobs on Brand, Audience and Dissemination Date, and enhancements to the 2253 Admin area.
Dale Cooke, an independent FDA regulatory expert at PhillyCooke Consulting said: “Making eCTD submissions available now shows that Zinc is committed to making the submission of post-marketing promotional materials to the FDA fast and simple. This gives Zinc clients the ability to begin implementing eCTD well ahead of it becoming a requirement and will help companies ensure compliance.” PhillyCooke Consulting helps companies develop compliant communications for FDA-regulated products.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance